IS6798A - Atorvastatínhálfkalsíum form VII - Google Patents
Atorvastatínhálfkalsíum form VIIInfo
- Publication number
- IS6798A IS6798A IS6798A IS6798A IS6798A IS 6798 A IS6798 A IS 6798A IS 6798 A IS6798 A IS 6798A IS 6798 A IS6798 A IS 6798A IS 6798 A IS6798 A IS 6798A
- Authority
- IS
- Iceland
- Prior art keywords
- form vii
- calcium form
- atorvastatin semi
- atorvastatin
- semi
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24589700P | 2000-11-03 | 2000-11-03 | |
| PCT/US2001/043947 WO2002041834A2 (en) | 2000-11-03 | 2001-11-05 | Atorvastatin hemi-calcium form vii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS6798A true IS6798A (is) | 2003-04-30 |
Family
ID=22928549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS6798A IS6798A (is) | 2000-11-03 | 2003-04-30 | Atorvastatínhálfkalsíum form VII |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6605636B2 (is) |
| EP (1) | EP1332130A4 (is) |
| JP (1) | JP2004513956A (is) |
| KR (1) | KR100704213B1 (is) |
| CN (1) | CN1535139A (is) |
| AU (1) | AU4150602A (is) |
| CA (1) | CA2426632C (is) |
| CZ (1) | CZ20031495A3 (is) |
| HR (1) | HRP20030442A2 (is) |
| HU (1) | HUP0303765A2 (is) |
| IL (2) | IL155734A0 (is) |
| IS (1) | IS6798A (is) |
| MX (1) | MXPA03003900A (is) |
| NO (1) | NO20031986D0 (is) |
| PL (1) | PL362472A1 (is) |
| SK (1) | SK6592003A3 (is) |
| WO (1) | WO2002041834A2 (is) |
| ZA (1) | ZA200303972B (is) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| WO2002051804A1 (en) * | 2000-12-27 | 2002-07-04 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of atorvastatin |
| CA2450111C (en) * | 2001-06-29 | 2006-02-07 | Warner-Lambert Company Llc | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
| US7074818B2 (en) | 2001-07-30 | 2006-07-11 | Dr. Reddy's Laboratories Limited | Crystalline forms VI and VII of Atorvastatin calcium |
| EP1414796A1 (en) * | 2001-07-30 | 2004-05-06 | Dr. Reddy's Laboratories Ltd. | Crystalline forms vi and vii of atorvastatin calcium |
| US20060020137A1 (en) * | 2001-11-29 | 2006-01-26 | Limor Tessler | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| MXPA04007939A (es) * | 2002-02-15 | 2004-11-26 | Teva Pharma | Formas cristalinas novedosas de hemi-calcio de atorvastatina y procesos para su preparacion; procesos novedosos para la preparacion de hemi-calcio de atorvastatina en sus formas i, viii i ix. |
| CN100379723C (zh) * | 2002-02-19 | 2008-04-09 | 特瓦制药工业有限公司 | 阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙 |
| EP1424324A1 (en) * | 2002-11-28 | 2004-06-02 | Teva Pharmaceutical Industries Limited | Crystalline form F of Atorvastatin hemi-calcium salt |
| WO2004050618A2 (en) * | 2002-11-28 | 2004-06-17 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
| FR2849029B1 (fr) | 2002-12-20 | 2005-03-18 | Lafon Labor | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| EP1614412A1 (de) * | 2003-11-18 | 2006-01-11 | Helm AG | Verfahren zur Herstellung von freifliessenden, pulverförmigen Atorvastatin-Adsorbaten |
| CA2560282A1 (en) * | 2004-03-17 | 2005-09-29 | Ranbaxy Laboratories Limited | Crystalline form of atorvastatin hemi calcium |
| PT1727795E (pt) | 2004-03-17 | 2012-04-11 | Ranbaxy Lab Ltd | Processo para a produção de atorvastatina cálcica na forma amorfa |
| ES2739493T3 (es) | 2004-05-05 | 2020-01-31 | Pfizer Prod Inc | Formas de sal de de atorvastatina con benetamina |
| ES2586561T3 (es) * | 2004-07-16 | 2016-10-17 | Lek Pharmaceuticals D.D. | Productos de degradación oxidativa de atorvastatina calcio |
| JP2008506764A (ja) | 2004-07-20 | 2008-03-06 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態 |
| DE202005020841U1 (de) * | 2004-09-28 | 2006-08-31 | Teva Pharmaceutical Industries Ltd. | Formen von Atorvastatin-Calcium, die im wesentlichen frei von Verunreinigungen sind |
| DE05810535T1 (de) * | 2004-10-18 | 2007-04-19 | Teva Pharmaceutical Industries Ltd. | Verfahren zur herstellung von amorphem atorvastatin-hemi-calcium durch lösen des salzes in einem organischen lösungsmittel, bei dem es sich um eine mischung enes alkohols und eines ketons und/oder eines esters handelt, und entfernen des lösungsmittels |
| AU2005298383A1 (en) | 2004-10-28 | 2006-05-04 | Warner-Lambert Company Llc | Process for forming amorphous atorvastatin |
| WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
| EA014079B1 (ru) * | 2005-04-08 | 2010-08-30 | Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг | Новая полиморфная форма кристаллической гемикальциевой соли аторвастатина |
| CA2547216A1 (en) * | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
| US8084488B2 (en) * | 2005-11-21 | 2011-12-27 | Pfizer Inc. | Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium |
| BRPI0520669A2 (pt) * | 2005-11-21 | 2009-06-02 | Teva Pharma | dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina |
| TW200745026A (en) | 2005-12-13 | 2007-12-16 | Teva Pharma | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
| EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
| WO2007103223A1 (en) * | 2006-03-01 | 2007-09-13 | Teva Pharmaceutical Industries Ltd. | Process for preparing a crystalline form of atorvastatin hemi-calcium |
| KR20080031487A (ko) * | 2006-06-28 | 2008-04-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토르바스타틴의 결정형 |
| US9334266B2 (en) | 2009-09-04 | 2016-05-10 | The University Of Toledo | Catalysts and related processes for producing optically pure beta-lactones from aldehydes and compositions produced thereby |
| KR20120011249A (ko) * | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
| PE20160945A1 (es) | 2013-11-15 | 2016-09-26 | Akebia Therapeutics Inc | Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acetico, composiciones, y usos de las mismas |
| KR101720894B1 (ko) | 2016-01-05 | 2017-03-30 | 김상우 | 무좀치료에 도움을 주는 건식 족욕기 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| HRP960313B1 (en) | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| PT1148049E (pt) | 1995-07-17 | 2005-02-28 | Warner Lambert Co | Formas cristalinas de hemi-sal de calcio do acido [r-(r*,r*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil)-1h-pirrole-1-heptanoico (atorvastatina) |
| US6087511A (en) | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
| ATE478665T1 (de) | 1999-11-17 | 2010-09-15 | Teva Pharma | Verfahren zur herstellung einer polymorphen form von atorvastatin calcium |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| WO2002051804A1 (en) * | 2000-12-27 | 2002-07-04 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of atorvastatin |
| WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| CA2450111C (en) * | 2001-06-29 | 2006-02-07 | Warner-Lambert Company Llc | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
| EP1414796A1 (en) * | 2001-07-30 | 2004-05-06 | Dr. Reddy's Laboratories Ltd. | Crystalline forms vi and vii of atorvastatin calcium |
-
2001
- 2001-11-05 PL PL01362472A patent/PL362472A1/xx not_active Application Discontinuation
- 2001-11-05 HU HU0303765A patent/HUP0303765A2/hu unknown
- 2001-11-05 CA CA 2426632 patent/CA2426632C/en not_active Expired - Fee Related
- 2001-11-05 MX MXPA03003900A patent/MXPA03003900A/es active IP Right Grant
- 2001-11-05 EP EP01988174A patent/EP1332130A4/en not_active Withdrawn
- 2001-11-05 US US09/992,746 patent/US6605636B2/en not_active Expired - Fee Related
- 2001-11-05 SK SK659-2003A patent/SK6592003A3/sk not_active Application Discontinuation
- 2001-11-05 JP JP2002544015A patent/JP2004513956A/ja not_active Withdrawn
- 2001-11-05 CZ CZ20031495A patent/CZ20031495A3/cs unknown
- 2001-11-05 WO PCT/US2001/043947 patent/WO2002041834A2/en not_active Application Discontinuation
- 2001-11-05 IL IL15573401A patent/IL155734A0/xx active IP Right Grant
- 2001-11-05 AU AU4150602A patent/AU4150602A/xx active Pending
- 2001-11-05 KR KR1020037006129A patent/KR100704213B1/ko not_active IP Right Cessation
- 2001-11-05 CN CNA018183840A patent/CN1535139A/zh active Pending
-
2003
- 2003-04-30 IS IS6798A patent/IS6798A/is unknown
- 2003-05-02 NO NO20031986A patent/NO20031986D0/no not_active Application Discontinuation
- 2003-05-04 IL IL155734A patent/IL155734A/en not_active IP Right Cessation
- 2003-05-22 ZA ZA200303972A patent/ZA200303972B/en unknown
- 2003-06-02 HR HR20030442A patent/HRP20030442A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040005854A (ko) | 2004-01-16 |
| PL362472A1 (en) | 2004-11-02 |
| IL155734A0 (en) | 2003-11-23 |
| CA2426632A1 (en) | 2002-05-30 |
| CA2426632C (en) | 2008-08-05 |
| ZA200303972B (en) | 2004-08-23 |
| EP1332130A2 (en) | 2003-08-06 |
| EP1332130A4 (en) | 2004-01-21 |
| KR100704213B1 (ko) | 2007-04-10 |
| US6605636B2 (en) | 2003-08-12 |
| IL155734A (en) | 2008-11-26 |
| NO20031986L (no) | 2003-05-02 |
| NO20031986D0 (no) | 2003-05-02 |
| AU4150602A (en) | 2002-06-03 |
| CZ20031495A3 (cs) | 2004-01-14 |
| WO2002041834A8 (en) | 2003-01-03 |
| HUP0303765A2 (hu) | 2004-03-01 |
| MXPA03003900A (es) | 2005-02-17 |
| US20020115709A1 (en) | 2002-08-22 |
| WO2002041834A2 (en) | 2002-05-30 |
| CN1535139A (zh) | 2004-10-06 |
| HRP20030442A2 (en) | 2005-06-30 |
| WO2002041834A3 (en) | 2002-07-18 |
| SK6592003A3 (en) | 2004-01-08 |
| JP2004513956A (ja) | 2004-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS6798A (is) | Atorvastatínhálfkalsíum form VII | |
| DZ3409A1 (fr) | Association therapeuthique | |
| ATE290000T1 (de) | Muscarinagonisten | |
| ATE252099T1 (de) | Biarylcarboxamide | |
| NO20010834L (no) | Flerbruks-rörfrakoblingsanordning | |
| DE10136334B8 (de) | Hochgeschwindigkeitsvertikalresonatoroberflächenemissionslaser | |
| DE60112185D1 (de) | Signalartbestimmung | |
| ATE312098T1 (de) | Thiazinoxazolidinon | |
| ATA2932001A (de) | Schneefräse | |
| DE60125415D1 (de) | Formeinsatz | |
| EE05197B1 (et) | Linesoliid - kristallivorm II | |
| DE50100710D1 (de) | Wischblatt | |
| ATE262530T1 (de) | Indolochinazolinone | |
| ATE298751T1 (de) | 7-oxopyridoryrimidine | |
| DE1274523T1 (de) | Hochdruckumformspülanlage | |
| DE10192638T1 (de) | Bohrstangenladevorrichtung | |
| AR028336A1 (es) | 4-hidroxi-tetrahidropiridonas fenilsubstituidas | |
| ATE509008T1 (de) | Sulfonylguanidine | |
| DE10196064T1 (de) | Halbleiterfotodektionsgerät | |
| DE50100817D1 (de) | Kugelgelenk | |
| DE50011511D1 (de) | Blowby-Heizung | |
| AR028061A1 (es) | 2-enamino-cetonitrilos fenil-substituidos | |
| AR027931A1 (es) | Antitranspirantes | |
| DE50007634D1 (de) | Kardioplegieballonkatheter | |
| ATE476423T1 (de) | Benzoylpyridazine |